Robert Levy - 25 Feb 2026 Form 4/A - Amendment Insider Report for HERBALIFE LTD. (HLF)

Reporting relationship: President
Issuer ticker: HLF
Reported as of: 25 Feb 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 03 Mar 2026, 21:25:58 UTC
Original report date: 27 Feb 2026
Prior SEC filing: 12 May 2026
Next SEC filing: 05 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Alaaeddine Sahibi, as Attorney-In-Fact for Robert Levy

Filing notes and source

Key filing fact

Robert Levy filed Form 4/A - Amendment for HERBALIFE LTD. (HLF) on 03 Mar 2026.

Key facts

This page summarizes Robert Levy's Form 4/A - Amendment filing for HERBALIFE LTD. (HLF).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 21:25.

Change

Previous filing in this sequence was filed on 12 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001311283 Primary reporting owner

LEVY ROBERT

Relationship: President
Address: 800 WEST OLYMPIC BLVD., SUITE 406, LOS ANGELES
Signature: /s/ Alaaeddine Sahibi, as Attorney-In-Fact for Robert Levy
Signature date: 03 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HLF transaction Derivative

Stock Appreciation Rights

Award

Transaction value: $0
Shares: +33,301
Change %
Price: $0.000000
Shares after: 33,301
Date: 25 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,301
Exercise price: $19.26
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This amendment is being filed solely to correct the exercise price, which was previously reported as $10.51. No other information in the original Form 4 has been changed.

Footnote F2

Consists of stock appreciation rights ("SARs") granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan. These SARs will vest in one-third increments on each of February 25, 2027, February 25, 2028, and February 25, 2029, subject to continued service through such date.